Shares of Gland Pharma hit a four-year high Monday, rising nearly 8 percent to Rs 3,374 apiece on the National Stock Exchange after the company reported strong earnings in the second quarter of the financial year 2026-27, driven by strong execution across businesses and robust sales in its key European and US markets. Besides, growth in its contract development and manufacturing organisation and critical injectables businesses supported performance in Q2 FY27.
Brokerages have expressed divergent views on Gland Pharma following the company's Q2 FY27 earnings, with Motilal Oswal and Axis Direct maintaining their 'Buy' recommendations, while Elara Capital downgraded the stock to 'Sell', citing expensive valuations and concerns over the sustainability of growth momentum.
Gland Pharma shares settled 4.86 percent higher at Rs 3,285. Earlier in the day, the stock opened at Rs 3,147 and rallied 7.69 percent to touch a 52-week high of Rs 3,372, which is also a four-year high.
Shares of the company rose 0.70 percent to closed Rs 3,169.4 apiece. The company declared its results after the market hours on Friday, November 6.
The shares are up nearly 8 percent in the past one month and around 27 percent in the past three months. The stock is up over nearly 78 percent in the last 52 weeks.